Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies. (Q33405714)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Phase Ia/II, two-arm, open-label, dose-escalation study of oral panobinostat administered via two dosing schedules in patients with advanced hematologic malignancies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

author name string

D J DeAngelo

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Spencer

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K N Bhalla

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

H M Prince

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

T Fischer

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

T Kindler

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

F J Giles

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

J W Scott

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K Parker

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

A Liu

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

M Woo

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

P Atadja

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

K K Mishra

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

publication date

6 February 2013

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

27

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

1628-1636

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

https://scigraph.springernature.com/pub.10.1038/leu.2013.38

0 references

Lysine acetylation targets protein complexes and co-regulates major cellular functions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Anticancer activities of histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Class II histone deacetylases are associated with VHL-independent regulation of hypoxia-inducible factor 1 alpha

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Targeting tumor angiogenesis with histone deacetylase inhibitors: the hydroxamic acid derivative LBH589.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Role of acetylation and extracellular location of heat shock protein 90alpha in tumor cell invasion

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Overview of Histone Deacetylase Inhibitors in Haematological Malignancies

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Combination strategy targeting the hypoxia inducible factor-1 alpha with mammalian target of rapamycin and histone deacetylase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Chemical genetic strategy identifies histone deacetylase 1 (HDAC1) and HDAC2 as therapeutic targets in sickle cell disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Cancer phase I clinical trials: efficient dose escalation with overdose control.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT).

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat in patients with relapsed/refractory Hodgkin's lymphoma after autologous stem-cell transplantation: results of a phase II study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Preliminary evidence of disease response to the pan deacetylase inhibitor panobinostat (LBH589) in refractory Hodgkin Lymphoma.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Deciphering the molecular and biologic processes that mediate histone deacetylase inhibitor-induced thrombocytopenia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Cotreatment with panobinostat and JAK2 inhibitor TG101209 attenuates JAK2V617F levels and signaling and exerts synergistic cytotoxic effects against human myeloproliferative neoplastic cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor and overcomes resistance to JAK2-TKI in human myeloproliferative neoplasm cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

The molecular biology of mixed lineage leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

H3K79 methylation profiles define murine and human MLL-AF4 leukemias

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

The synergy of panobinostat plus doxorubicin in acute myeloid leukemia suggests a role for HDAC inhibitors in the control of DNA repair

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Aggresome induction by proteasome inhibitor bortezomib and alpha-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase 2 trial of romidepsin in patients with peripheral T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

MLL-aberrant leukemia: complete cytogenetic remission following treatment with a histone deacetylase inhibitor (HDACi)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

Bortezomib for AL amyloidosis: moving forward

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

21 January 2018

StatBite: FDA oncology drug product approvals in 2009

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Rapid recovery from panobinostat (LBH589)-induced thrombocytopenia in mice involves a rebound effect of bone marrow megakaryocytes

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2013.38

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2013.38

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Dimensions Publication ID

0 references

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23385375%20AND%20SRC:MED&resulttype=core&format=json

23 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33405714&oldid=1607221709"